Worldwide Cervical Cancer Treatment Market Size & Share to 2026, Featuring Profiles for Key Players - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Feb 6, 2019--The “Global Cervical Cancer Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026” report has been added to ResearchAndMarkets.com’s offering.
The global cervical cancer treatment market is expected to expand at a CAGR of 5.2% from 2018 to 2026.
According to the latest research citings of the World Health Organization (WHO) in 2018, approximately 570,000 new cases if cervical cancer were reported which eventually represents 6.6% of all female cancers.
The early manifestation of cervical cancer is vaginal bleeding after sexual intercourse with excruciating pain. The 2 main types of cervical cancer are squamous cell carcinoma and adenocarcinoma. Early diagnosis and vaccination with Gardasil can prevent the advent of cervical cancer.
In the last decade, there has been a paradigm shift in the treatment regimen from chemotherapy to targeted therapy. Biologics in phase III clinical trials such as nimotuzumab and atezolizumab will provide a positive thrust to the cervical cancer treatment market growth.
Chemotherapy is reigning the product segment for the cervical cancer treatment market. Paclitaxel, cisplatin, carboplatin, gemcitabine are given either alone or in combination with radiation therapy for patients suffering from advanced stage cervical cancer. The combination therapy is helpful but causes severe adverse effects. Cervical hysterectomy is helpful in women suffering from early-stage cervical cancer. Targeted drug therapy will be the fastest growing market on account of its excellent clinical outcomes, dose tolerability, and patient compliance.
North America presently maintains supremacy in the regional segment for cervical cancer treatment market. According to Center for Disease Control and Prevention (CDC), cervical cancer is the second most common type of cancer in women after breast cancer resulting in mortality due to lack of early screening and medical intervention. Rising public health awareness and affordable reimbursement scenario drive the cervical cancer treatment market growth in North America.
In Europe, cervical cancer is responsible for the mortality of 70% patient actively diagnosed with cervical cancer. Presence of key players such as F.Hoffman La-Roche, Merck & Co, and GlaxoSmithKline etc. propel the cervical cancer treatment market growth in the European Region.
The Asia Pacific will be the fastest growing market during the forecast period owing to the presence of huge generic market and proactive government policies to fight cervical cancer.
Key Market MovementsIncreasing cases of women being diagnosed for cervical cancer throughout the globe Rising public health awareness and affordable reimbursement scenario for the generic drugs employed for the treatment of cervical cancer Vaccination such as Gardasil is helpful in the prevention of HPV infection and strong biologics pipeline with drugs in phase III clinical trials such as nimotuzumab and atezolizumab
Chapter 1. Preface
Chapter 2. Executive Summary
2.1. Global Cervical Cancer Treatment Market Portraiture
2.2. Global Cervical Cancer Treatment Market, by Product, 2017 (US$ Mn)
2.3. Global Cervical Cancer Treatment Market, by Geography, 2017 (US$ Mn)
Chapter 3. Cervical Cancer Treatment Market: Dynamics and Future Outlook
3.1. Market Overview
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Cervical Cancer Treatment Market, by Key Players, 2017
Chapter 4. Global Cervical Cancer Treatment Market, by Product
4.3. Targeted Therapy
4.4. Surgical Procedure
4.5. Radiation Therapy
4.7. Pipeline Analysis
Chapter 5. Global Cervical Cancer Treatment Market, by Geography
5.2. North America Cervical Cancer Treatment Market Analysis, 2016-2026
5.3. Europe Cervical Cancer Treatment Market Analysis, 2016-2026
5.4. Asia Pacific Cervical Cancer Treatment Market Analysis, 2016-2026
5.5. Latin America Cervical Cancer Treatment Market Analysis, 2016-2026
5.6. Middle East and Africa Cervical Cancer Treatment Market Analysis, 2016-2026
Chapter 6. Company Profiles
6.1. Allergan PLC
6.2. Biocon Ltd.
6.3. CooperSurgical Inc.
6.4. Eli Lilly & Company
6.5. F.Hoffman La-Roche AG
6.6. GlaxoSmithKline PLC
6.7. Ethicon Inc.
6.8. Merck & Co. Inc.
6.9. Teva Pharmaceutical Industries Ltd.
6.10. Varian Medical Systems Inc.
For more information about this report visit https://www.researchandmarkets.com/research/w7srtf/worldwide?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190206005346/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Cervical Cancer Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 02/06/2019 07:32 AM/DISC: 02/06/2019 07:32 AM